ClinicalTrials.gg
Status unknownNCT03902704Updated May 16, 2022

Safety and Efficacy of Cleverscope. A New Medical Device for Tracheal Intubation

An interventional study of Cleverscope and Laryngoscope / Videolaryngoscope C-MAC® Storz in Anesthesia Intubation Complication and Difficult Intubation, sponsored by Hospital General Universitario de Valencia. Status unknown at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-16.

Sponsored by Hospital General Universitario de Valencia · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Cleverscope is a new medical device that transform a laryngoscope into a videolaryngoscope. previous its commercialization we evaluate its safety and efficacy.

Read the detailed description

the investigators develope two part study. part I: the investigators collect data of 50 patients prospectively programed for general anesthesia and tracheal intubation without predictors of difficult airways. this patients were intubated with cleverscope, the investigators register best cormack-lehane (glottic vision) obtained with Cleverscope and best cormack obtained with direct laryngoscopy. the investigators register intubation succes rate and any complications during its use and after extubation.

part II: after confirm safety and efficacy in patients without difficult airways (part I) the investigators use Cleverscope for the same pourpose on difficult airways patients. collecting same data . the investigators compare cormack-lehane in this patients with Cleverscope and commercial Videolaryngoscope C-MAC.

02

Conditions studied

  • Anesthesia Intubation Complication
  • Difficult Intubation

Keywords

  • videolaryngoscopy
  • tracheal intubation
03

In context

Lead sponsor

Hospital General Universitario de Valencia is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • part 1: Scheduled Patients for any kind of surgery with general anesthesia with tracheal intubation without predictors of difficult intubation :

    1. Arne Test \< 10
    2. cervical circunference / tyromental distance \< 4.
  • part 2: Scheduled Patients for any kind of surgery with general anesthesia with tracheal intubation with predictors of difficult intubation :

    1. Arne Test > 10
    2. cervical circunference / tyromental distance > 4.

Exclusion criteria

Exclusion Criteria:

  • no mouth openning >2cm
  • required use of awake fiberscope por tracheal intubation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Cleverscope

    Cleverscope is a new videolaryngoscope used for tracheal intubation. in this group we use this device to intubate participants.

    Device: Cleverscope

  • Active comparator
    Laryngoscope / Videolaryngoscope C-MAC® Storz

    in this group we use a standart comercial device for intubation (laryngoscope or C-MAC) to intubate participants

    Device: Laryngoscope / Videolaryngoscope C-MAC® Storz

Interventions

  • DeviceCleverscope

    the device is used in patients without difficult airways predictors

  • DeviceLaryngoscope / Videolaryngoscope C-MAC® Storz

    the device is used in patients with difficult airways predictors

06

What researchers measure

Primary outcomes

  1. Cormack-Lehane Glotic visualization scale (I(complete view, easy to intubate)-IV(no view, imposible to intubate)

    degree of glotis visualization

    Time frame: intraoperative

Secondary outcomes

  1. First attempt intubation success rate

    the rate of traqueal tube pass through vocal cords at first attemps.

    Time frame: intraoperative

  2. overall success intubation rate with same device

    it could include more attempts

    Time frame: intraoperative

  3. time to success

    time wasted from device inserted into mouth to inflate tracheal tube

    Time frame: intraoperative

  4. complications rate

    register complications during intubation or due device usage. like hemorrage, mucosal laceration,

    Time frame: intraoperative

07

Study locations

1 of 1 sites recruiting
  • Lucas Rovira
    La Pobla De Vallbona, Valencia 46185, Spain
    Recruiting
    • Lucas Rovira, PhD · Contactlucasrovira@gmail.com · +34659276476
    • Lucas Rovira, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2019 (actual). Primary completion is estimated for Oct 2023, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2019
First posted
Apr 4, 2019
StartActual
Oct 1, 2019
Primary completionEst.
Oct 1, 2023
CompletionEst.
Dec 1, 2023
Last update
May 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03902704
Lead sponsor
Hospital General Universitario de Valencia
Collaborators
FIPSE
Responsible party
Lucas Rovira (Principal Investigator, Hospital General Universitario de Valencia) — Principal investigator
First posted
Apr 4, 2019
Start date
Oct 1, 2019
Primary completion
Oct 1, 2023 (estimated)
Completion
Dec 1, 2023 (estimated)
Last update
May 16, 2022

Study contacts

Lucas Rovira, PhD
Contact
lucasrovira@gmail.com
+34659276476

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion